| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 23 May 2025 | 12 May 2025 |
| Biogen Pharmachem Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2025 inter alia to consider and approve PFA This is to inform you that Outcome of the Board Meeting of the Company held on Friday 23rd May, 2025 in accordance with SEBl (Listing Obligations and Disclosures Requirements) Regulations, 2015, has been approved by the Board of Directors of the Company and taken on record inter-alia the following items; 1.) Consideration and Approval of Audited Financial Result for the Year ended 31st March, 2025. 2.) Independent Audit Report in pursuance with Regulation 33 of SEBI (LODR) Regulations, 2015 for the F.Y. 31st March, 2025. Further, we hereby declare that the Auditor of the Company has issued the Audit report under the Companies Act, 2013 and financial results as prepared under SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 for the financial year ended on March 31, 2025 with unmodified opinion. The board meeting commenced on 04:45 PM and concluded on 05:30PM Request you to kindly take on record the same. Thanking You. (As Per BSE Announcement Dated on: 23/05/2025) | ||
| Board Meeting | 15 Apr 2025 | 15 Apr 2025 |
| This is to Inform you that at the Meeting of the Board of Directors of the Company held today on Tuesday, 15th April 2025 It has further informed that all final call is called up on 08.04.2025 and so now warrants are fully paid up and converted into equity shares of the Company on the preferential basis and allotted as the pdf attached. The meeting commenced at 03:30 P.M. and concluded at 04:00 P.M. : Please take this on your record. This is for your information Thanking You. | ||
| Board Meeting | 8 Apr 2025 | 8 Apr 2025 |
| Board Meeting Outcome for Outcome Of Board Meeting Held On Today 08.04.2025. | ||
| Board Meeting | 21 Mar 2025 | 21 Mar 2025 |
| We wish to inform that the Board of Directors in their meeting held today, i.e., March 21, 2025, inter-alia, considered and approved the following items: 1. Allotment of 25,00,00,000 (Twenty-Five Crore Only) equity share warrants to non-promoters on Preferential Basis at an issue price of Rs. 1.68/- (Rupees one and sixty-eight paise) each upon receipt of other 5% of the total consideration. The above said allotments have been made in accordance with the terms mentioned in the notice of Postal Ballot dated 13.08.2024 and in compliance with the applicable provisions of the Companies Act, 2013 and SEBI (ICDR) Regulations. Disclosures pursuant to the Regulation 30 of the SEBI (LODR) Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 is attached as Annexure A. The meeting commenced at 04:00 P.M. and concluded at 04:30 P.M. This is for your information. | ||
| Board Meeting | 11 Mar 2025 | 11 Mar 2025 |
| We wish to inform that the Board of Directors in their meeting held today, i.e., March 11, 2025, inter-alia, considered and approved the following items: 1. Allotment of 25,00,00,000 (Twenty-Five Crore Only) equity share warrants to non-promoters on Preferential Basis at an issue price of Rs. 1.68/- (Rupees one and sixty-eight paise) each upon receipt of other 5% of the total consideration. The above said allotments have been made in accordance with the terms mentioned in the notice of Postal Ballot dated 13.08.2024 and in compliance with the applicable provisions of the Companies Act, 2013 and SEBI (ICDR) Regulations. Disclosures pursuant to the Regulation 30 of the SEBI (LODR) Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 is attached as Annexure A. The meeting commenced at 03:30 P.M. and concluded at 04:05 P.M. This is for your information. | ||
| Board Meeting | 7 Mar 2025 | 7 Mar 2025 |
| We wish to inform that the Board of Directors in their meeting held today, Le., March 7, 2025, inter-alia, considered and approved the following items: 1. Allotment of 25,00,00,000 (Twenty-Five Crore Only) equity share warrants to nonpromoters on Preferential Basis at an issue price of Rs. 1.68/- (Rupees one and sixty-eight paise) each upon receipt of other 5% of the total consideration. The above said allotments have been made in accordance with the terms mentioned in the notice of Postal Ballot dated 13.08.2024 and in compliance with the applicable provisions of the Companies Act, 2013 and SEBI (ICDR) Regulations. Disclosures pursuant to the Regulation 30 of the SEBI (LODR) Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9,2015 is attached as Annexure A. The meeting commenced at 03:30 P.M. and concluded at 04:00 P.M. This is for your information. Thanking You. | ||
| Board Meeting | 5 Feb 2025 | 22 Jan 2025 |
| Biogen Pharmachem Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2025 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that a meeting of the Board of Directors of the Company will be held on Wednesday 5th February 2025 inter alia to consider following business. - 1.) To approve and take on record the Un-Audited Financia l Results of the Company for the quarter ended on 31t December 2024. 2.) To approve and consider the appointment of Mr. Kelash Bunkar as Whole time Director and Chief Financial Officer of the Company. 3.) To consider the resignation of Mr. Niraj Vaghela from designation of Whole time Director and Chief Financial Officer of the Company. 4.)To approve and consider the appointment of Mr. Aman Patel as Director of the Company. 5.) To consider the resignation of Ms. Komal Chauhan from directorship of the Company. 6.) Any other matter with the permission of the board which the Board may think fit. Thanking You. 1.) Considered and approved Un-audited financial results for the quarter and nine months ended on 31st December 2024. 2.) The board has considered and approved the appointment of Mr. Kelash Bunkar as Whole-time Director and Chief Financial Officer of the Company w.e.f 05.02.2025. 3.) The board has considered and accepted the resignation of Mr. Niraj Vaghela from designation of Whole time Director and Chief Financial Officer of the Company w.e. f 05.02.2025 4.) Mr. Aman Patel is appointed as non-executive independent director of the company w .e. f. 05.02.2025 subject to approval of members. 5.) The board has considered and accepted the of Independent Director Ms Komal Chauhan w e.f 05.02.2025. The board meeting commenced at 03:30 PM and concluded at 04:25 PM (As per BSE Announcement Dated on 05/02/2025) | ||
| Board Meeting | 17 Jan 2025 | 17 Jan 2025 |
| We wish to inform that the Board of Directors in their meeting held today, i.e., January 17 2025, inter-alia, considered and approved the following items: 1. Allotment of 25,00,00,000 (Twenty-Five Crore Only) equity share warrants to non-promoters on Preferential Basis at an issue price of Rs. 1.68/- (Rupees one and sixty-eight paise) each upon receipt of other 40% of the total consideration. The above said allotments have been made in accordance with the terms mentioned in the notice of Postal Ballot dated 13.08.2024 and in compliance with the applicable provisions of the Companies Act, 2013 and SEBI (ICDR) Regulations. Disclosures pursuant to the Regulation 30 of the SEBI (LODR) Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 is attached as Annexure A. The meeting commenced at 05:00 P.M. and concluded at 05:30 P.M. This is for your information. Thanking You. | ||
| Board Meeting | 29 Nov 2024 | 29 Nov 2024 |
| We wish to inform that the Board of Directors in their meeting held today, i.e., 29th November 2024, inter-alia, considered and approved the following items: 1. Allotment of 25,00,00,000 (Twenty Five Crore Only) equity share warrants to non-promoters on Preferential Basis at an issue price of Rs. 1.68/- (Rupees one and sixty eight paise) each upon receipt of 25% of the total consideration. The above said allotments have been made in accordance with the terms mentioned in the notice of Postal Ballot dated 13.08.2024 and in compliance with the applicable provisions of the Companies Act, 2013 and SEBI (ICDR) Regulations. Disclosures pursuant to the Regulation 30 of the SEBI (LODR) Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 is attached as Annexure A. The meeting commenced at 5:30 P.M. and concluded at 06:00 P.M. This is for your information Thanking You. | ||
| Board Meeting | 13 Nov 2024 | 15 Oct 2024 |
| Biogen Pharmachem Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2024 inter alia to consider and approve PFA Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of t he SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of the Company, in their meeting held on today i.e. Wednesday 13th November 2024 at the Registered Office of the Company and transacted the following major businesses: 1.) Considered and approved Un-audited financial results for the quarter ended as on 30th September, 2024. The meeting commenced at 05.30 P.M. and concluded at 06.00 P.M. Kindly take the same on your record and oblige. Thanking You. (As per BSE Announcement Dated on 13/11/2024) | ||
| Board Meeting | 13 Aug 2024 | 1 Aug 2024 |
| Biogen Pharmachem Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2024 inter alia to consider and approve PFA Biogen Pharmachem Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2024 ,inter alia, to consider and approve Pursuant to regulation 29(1)(d) and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, we wish to inform you that the meeting of Board of Director of the Company which is going to be held today Friday, August 9 2024 stands postponed due to unavoidable circumstances and rescheduled on 13th August 2024 (As per BSE Announcement Dated on 09/08/2024) PFA (As per BSE Announcement dated on 13/08/2024) | ||
| Board Meeting | 1 Aug 2024 | 25 Jul 2024 |
| Biogen Pharmachem Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/08/2024 inter alia to consider and approve 1.) To approve and take on record the Un-Audited Financial Results of the Company for the quarter ended on 30th June 2024. 2.) Any other matter with the permission of the board which the Board may think fit. Please take the above intimation in your records. Thanking You. PFA (As per BSE Announcement Dated on 01/08/2024) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.